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Abstract
Constitutive activation of the transcription factor Stat5 in hematopoietic stem/progenitor cells leads to various
hematopoietic malignancies including myeloproliferative neoplasm (MPN). Our recent study found that phospholipase C
(PLC)-b3 is a novel tumor suppressor involved in MPN, lymphoma and other tumors. Stat5 activity is negatively regulated by
the SH2 domain-containing protein phosphatase SHP-1 in a PLC-b3-dependent manner. PLC-b3c a nf o r mt h e
multimolecular SPS complex together with SHP-1 and Stat5. The close physical proximity of SHP-1 and Stat5 brought
about by interacting with the C-terminal segment of PLC-b3 (PLC-b3-CT) accelerates SHP-1-mediated dephosphorylation of
Stat5. Here we identify the minimal sequences within PLC-b3-CT required for its tumor suppressor function. Two of the
three Stat5-binding noncontiguous regions, one of which also binds SHP-1, substantially inhibited in vitro proliferation of
Ba/F3 cells. Surprisingly, an 11-residue Stat5-binding peptide (residues 988-998) suppressed Stat5 activity in Ba/F3 cells and
in vivo proliferation and myeloid differentiation of hematopoietic stem/progenitor cells. Therefore, this study further defines
PLC-b3-CT as the Stat5- and SHP-1-binding domain by identifying minimal functional sequences of PLC-b3 for its tumor
suppressor function and implies their potential utility in the control of hematopoietic malignancies.
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Introduction
The development and homeostasis of hematopoietic cells is
controlled by the actions of a multitude of cytokines, growth
factors, and hormones [1]. Cell surface receptors bound by these
ligands activate several signaling pathways including the Jak-Stat
(signal transducer and activator of transcription) pathway. The
Jak-Stat pathway plays a crucial role in a number of biological
functions by activating transcription of numerous genes [2,3,4].
Cytokine stimulation activates Jak kinases through transphosphor-
ylation and results in tyrosine phosphorylation of receptor sites,
Stats, and other substrates. Following tyrosine phosphorylation,
Stats homo- or hetero-dimerize, translocate to the nucleus, and
activate gene expression through sequence-specific response
elements. Among seven mammalian Stat proteins (1–4, 5A, 5B,
and 6), Stat5 encoded by two closely linked genes, Stat5a and
Stat5b, plays a crucial role in the commitment of embryonic stem
cells to hematopoietic cells [5], early hematopoiesis [6,7], and
proliferation and differentiation of myeloid [8] and lymphoid cells
[9]. Retroviral transduction of hematopoietic stem cells (HSCs)
with constitutively active Stat5 promotes self-renewal, prolifera-
tion, and survival of HSCs and induces a lethal myeloproliferative
neoplasm (MPN) in mice that have received the transduced cells
[10]; constitutively active Stat5 in lymphocytes leads to increased
numbers of pro-B and pre-B cells as well as CD4 and CD8 T cells
and acute lymphoblastic leukemia [11,12].
Phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-
bisphosphate to generate diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). DAG can activate several isoforms of protein
kinase C, and IP3 can mobilize Ca
2+. PLC-b isoforms (b1–b4) work
as effectors and inactivators for the Gq family of heterotrimeric G
proteins. Agonist-stimulated receptors increase exchange of GTP
for GDP on Gaq, GTP-bound Gaq engages and activates PLC-b,
and PLC-b increases the rate of GTP hydrolysis [13,14,15]. These
functions of PLC-b determine the duration, amplitude, and on-off
cycling of the signaling. Unexpectedly from these G-protein-related
studies, we showed that PLC-b3
2/2 mice develop a late-onset MPN
[16]. The mutant mice have increased numbers of HSCs with
increased proliferative, survival, and myeloid-differentiative abili-
ties.Theseproperties aredependent onconstitutiveactivationofthe
transcription factor Stat5 and can be antagonized by the SH2
domain-containing protein phosphatase SHP-1. PLC-b3 functions
as a scaffold to interact with Stat5 and SHP-1 via its noncatalytic C-
terminal domain (PLC-b3-CT) to form the multimolecular SPS
complex [16]. PLC-b3 facilitates SHP-1-mediated dephosphoryla-
tion and inactivation of Stat5. Consistent with this, SHP-1 loss-of-
function mutant (motheaten viable, me
v) mice also develop MPN,
phenocoping PLC-b3
2/2 mice. However, the MPN in me
v/me
v mice
is more rapid and fatal than that in PLC-b3
2/2 mice. Moreover,
me
v/me
v, but not PLC-b3
2/2, mice develop anemia, a phenomenon
often observed in myelodysplastic syndrome.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24995The above mouse studies seem relevant to human diseases.
Stat5-dependent cooperative transformation by active c-Myc and
PLC-b3 deficiency was suggested in mouse lymphomas in PLC-
b3
2/2 and in Em-myc;PLC-b3
+/2 mice as well as in human
Burkitt’s lymphoma cells [16]. The same mechanism for malignant
transformation seems to be operative in other human lymphoid
and myeloid malignancies.
Similar to other scaffold proteins [17], PLC-b3 consists of
modular structures including the pleckstrin homology (PH), four
EF hands, split catalytic TIM barrel, C2, and CT domains in this
order from the N- to C-termini. PH domains are important for
recruiting proteins to different membranes by interacting with
phospholipids such as phosphatidylinositol 3,4,5-trisphosphate and
phosphatidylinositol 4,5-bisphosphate [18] and proteins such as
protein kinase C [19] and the bc subunits of heterotrimeric G
proteins [20,21], although the PH domains of PLC-b2 or PLC-b3
did not bind several phosphatidylinositols (data not shown);
EF hands are Ca
2+-binding helix-loop-helix domains [22]; C2
domains are involved in calcium-dependent phospholipid binding
and in membrane targeting [23,24]. A recent study identified three
Gaq-binding regions in PLC-b3 [25]: the short helix-turn-helix
(Ha1 and Ha2) region following the C2 domain and the loop
between the TIM barrel and C2 domain are critical for PLC
catalytic activity; the third Gaq-interacting region, EF hands 3 and
4, are critical for GTP hydrolysis by Gaq. PLC-b also interacts
with and is activated by, the bc complex. In this study we
attempted to identify minimal sequences of PLC-b3-CT required
for its tumor suppressor function.
Results
Noncontiguous multiple short peptides within PLC-b3-CT
bind to Stat5 and SHP-1
Our previous study showed that PLC-b3-CT has the tumor
suppressor function and contains the interaction sites for Stat5 and
SHP-1 [16]. To further our understanding how PLC-b3 performs
its growth-suppressive function, we attempted to finely map the
Stat5- and SHP-1-binding sites within PLC-b3-CT (residues 809–
1234). To this end, we performed pull-down experiments using a
large panel of GST fusion proteins containing various portions of
PLC-b3-CT. We designed the fusion constructs that allowed us to
narrow down the binding sites within less than 40 amino acid
residues. Initially, a series of GST constructs with N-terminal
deletions and C-terminal deletions were used to map a Stat5-
binding site at residues 917-943 (Fig. 1A, Left) and another at
residues 1032–1069 (Fig. 1A, Right). Using smaller fragments, we
could map another Stat5-binding site at 983–1000 (Fig. 1B). SHP-
1-binding sites were similarly mapped (Fig. 2). Results with more
than 30 GST fusion proteins are summarized in Fig. 3, showing
only the constructs essential to determine the binding sites. Three
noncontiguous regions, designated a (positions 917–943), b
(positions 983–1000), and c (positions 1032–1069), bound to Stat5
Figure 1. Mapping the Stat5-binding sites within PLC-b3-CT. (A, B) Lysates of Ba/F3 cells incubated with or without IL-3 were mixed with GST
fusion proteins, then beads-bound proteins were analyzed by SDS-PAGE followed by immnoblotting with anti-Stat5 antibody. The same blots were
reprobed with anti-GST. PLC-b3 portions of GST fusion proteins used are shown by residue numbers. TCL, total cell lysates. The 983–1234 fusion
protein (PC) was used as a positive control while GST was used as a negative control.
doi:10.1371/journal.pone.0024995.g001
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1182–1209) bound to SHP-1. Thus, region c could bind both Stat5
and SHP-1.
Stat5-binding short peptides inhibit the in vitro growth
of Ba/F3 and TF-1 cells
Stat5 is a critical transcription factor for the proliferation,
survival, and differentiation of HSCs in PLC-b3
2/2 mice [16].
Thus, we tested whether overexpression of Stat5-interacting
peptides affects the in vitro growth of hematopoietic cells. First,
these peptides (i.e., peptides a–d) were overexpressed as N-
terminally Myc-tagged peptides in Ba/F3 cells. PLC-b3-CT was
overexpressed 22 times more than endogenous PLC-b3 in Ba/F3
cells (Fig. 4A), as shown previously [16]. Expression of PLC-b3-
CT suppressed the IL-3-dependent growth of Ba/F3 cells by
,40% after 5 days in culture, compared to transduction with
empty vector. Importantly, two Stat5-interacting peptides b and c
showed significant inhibition of the cell growth (Fig. 4A). Similar
growth inhibition by peptides b and c was observed with TF-1
erythroleukemia cells (Fig. 4B). However, the Stat5-binding
peptide a inhibited Ba/F3 cells or TF-1 only slightly. The SHP-
1-binding peptide d and a non-Stat5/SHP-1-binding peptide
(1114–1132) exhibited no growth-inhibitory activity in Ba/F3 or
TF-1 cells. These results suggest that Stat5 binding activity of
peptides b and c may be critical for growth suppression. Because
peptide b exhibited approximately 80% potency of PLC-b3-CT in
Ba/F3 growth inhibition, we tested eleven shorter peptides in this
region in the Ba/F3 inhibition assays. Among them, an 11-residue
peptide (peptide b11; positions 988–998) exhibited a growth-
inhibitory activity as .80% strong as PLC-b3-CT (Fig. 4C).
Expression of the Stat5-interacting peptide b11 inhibits
Stat5 phosphorylation
To decipher the molecular mechanism for the peptide b11-
induced growth inhibition, IL-3-dependent signaling pathways
were analyzed in the tranduced Ba/F3 cells. As shown in
Fig. 5A, immunoblotting analysis showed that Stat5 phosphor-
ylation at Tyr
694 was significantly reduced in peptide b11-
expressing and PLC-b3-CT-expressing cells. By contrast, Stat3
phosphorylation at Tyr
705 was not suppressed by peptide b11 or
PLC-b3-CT. Immunofluorescence microscopy showed reduced
numbers of the peptide b11-expressing and PLC-b3-CT-
expressing cells that have high phosphorylation levels of Stat5-
Tyr
694 (Fig. 5B).
Phosphorylation of Akt (both at Thr
308 and Ser
473) was also
slightly reduced. By contrast, phosphorylation of MAP kinases
(ERK1/2, JNK1/2, p38) at their critical Tyr and Thr residues was
rather slightly increased in peptide b11-expressing and PLC-b3-
CT-expressing cells, compared to control cells (Fig. 6A). Given
these results, we evaluated the sensitivity of these cells to inhibitors
of the PI3K, ERK, JNK and p38 pathways. The growth of control
Ba/F3 cells was inhibited by wortmannin and LY294002 (PI3K
inhibitors), U0126 (MEK inhibitor), SP600125 (JNK inhibitor)
and SB203580 (p38 inhibitor) in a time-dependent manner
(Fig. 6B). By contrast, the peptide b11-expressing and PLC-b3-
CT-expressing Ba/F3 cells were less sensitive to these inhibitors.
These results are consistent with the notion that inhibition of Stat5
is more important than that of other signaling pathways such as
PI3K/Akt and MAPK pathways for the suppression of in vitro
growth of PLC-b3-CT-expressing Ba/F3 cells.
Figure 2. Mapping the SHP-1-binding sites within PLC-b3-CT. GST pulldown experiments were performed similar to those shown in Fig. 1.
The 983-1234 fusion protein (PC) was used as a positive control while GST was used as a negative control.
doi:10.1371/journal.pone.0024995.g002
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colony formation
We previously showed that several-fold more myeloid colonies were
generated in methylcellulose medium from BM cells or HSCs from
PLC-b3
2/2 mice than from WT counterparts [16]. Thus, we
examined the effect of peptide b11 and PLC-b3-CT on in vitro myeloid
cell differentiation. Lineage
2(Lin
2) BM cells expressing peptide b11 or
PLC-b3-CT grew at reduced rates compared to control cells (Fig. 7A)
and formed reduced numbers of myeloid colonies (Fig. 7B).
The Stat5-interacting peptide b11 inhibits MPN
development
Our previous study demonstrated that retroviral expression of
PLC-b3-CT in PLC-b3-deficient CD34
2c-Kit
+Sca-1
+Lin
2 cells
(enriched in long-term HSCs [26]) inhibits the development of
MPN when transplanted into lethally irradiated mice [16]. Having
shown the strong growth-inhibitory potency of peptide b11, we
tested whether expression of this short peptide might suppress the
MPN-inducing ability of PLC-b3-deficient HSCs. Lin
2 BM cells
from PLC-b3
2/2 mice (CD45.2
+) were retrovirally transduced with
PLC-b3-CT.When thesecellsweretransferred tolethallyirradiated
C57BL/6-Ly5.1 mice (CD45.1
+) together with Sca-1-depleted
C57BL/6-Ly5.1 helper BM cells, MPN development was sup-
pressed (Fig. 7C–D), as shown previously [16]. .90% CD11b
+
cells in the peripheral blood were Gr-1
+ mature granulocytes and
50–60% of CD45.2
+ cells were GFP
+. Peptide b11-expressing lin
2
BM cells also exhibited the ability to suppress MPN development.
Thus, peptide b11 transduction also likely targeted long-term
HSCs. Interestingly, transplantation of empty vector-, peptide b11-
or PLC-b3-CT-transduced cells did not significantly affect the
number of host-derived CD11b
+ cells (Fig. 7E).
Discussion
Using GST fusion pulldown assays, three and two noncontig-
uous segments of ,40 residues were identified as Stat5- and SHP-
1-binding sites, respectively, within PLC-b3-CT. When overex-
pressed, the Stat5-binding peptide b and the Stat5/SHP-1-binding
peptide c exhibited an ability to inhibit two hematopoietic cells,
i.e., Ba/F3 pro-B cells and TF-1 erythroleukemia cells. Peptide b
and its shorter derivative b11 were strong inhibitors with ,80%
potency of PLC-b3-CT. As with PLC-b3-CT, peptide b11
inhibited in vitro myeloid cell proliferation and differentiation and
suppressed the MPN-inducing ability of PLC-b3
2/2 HSC.
Consistent with our previous study [16], reduced Stat5 activity
seems to be a molecular basis for the growth-inhibitory function
of PLC-b3-CT and its shorter derivatives such as peptide b and
b11. The peptides that showed substantial inhibitory activity all
had Stat5-binding activity and the cells expressing these peptides
showed reduced Stat5-Tyr
694 phosphorylation. Interestingly,
phosphorylation of MAPKs was slightly increased and Akt
phosphorylation was slightly decreased in peptide b11- and
Figure 3. Summary of fine mapping of Stat5- and SHP-1-binding sites within PLC-b3-CT. The deduced Stat5- and SHP-1-binding sites are
shown at the bottom. Only GST fusion constructs used to determine the binding sites are shown. nd, not determined.
doi:10.1371/journal.pone.0024995.g003
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detected by immunoblotting might not be detected by flow
cytometry of intracellularly stained molecules. Probably, this
could be the reason why we failed to observe differences in Akt
and MAPKs phosphorylation between WT and PLC-b3
2/2
HSCs in our previous study [16]. However, the differences in Akt
and MAPKs phosphorylation in peptide b11- and PLC-b3-CT-
overexpressing vs. control Ba/F3 cells may not be physiologically
relevant. Inhibitor experiments showed that peptide b11- and
PLC-b3-CT-overexpressing Ba/F3 cells are less sensitive to
growth inhibition by MAPK and PI3K inhibitors than control
Ba/F3 cells. These results suggest that IL-3-dependent Ba/F3
cells depend their growth mainly on Stat5, but not MAPKs or
Akt. Thus, it will be interesting to examine whether PLC-b3
2/2
HSCs are less sensitive to MAPK and PI3K inhibitors than WT
HSCs.
The C-terminal domain of avian PLC-b is composed of three
long helices forming a coiled-coil that dimerizes along its long axis
in an antiparallel orientation [27]. All the Stat5-binding and SHP-
1-binding sites were mapped to this region, C-terminal to the
Gaq-binding helix-turn-helix (Ha1 and Ha2) region. Homology
search using the amino acid sequence of peptide b11 (residues
988–998) identified parasite and bacterial sequences with
significant homology in their hypothetical proteins (Fig. 8),
whereas search with the same stringency failed to detect
homologous sequences in the genomes of eukaryotes and
prokaryotes with peptides a, c, or d (data not shown). If the
peptides with homology to peptide b have the ability to inhibit
Stat5 activity as shown for peptide b11, such an activity might be
important for virulence of the parasites and bacteria.
Introduction of peptides into target cells could be a potential
therapeutic strategy for the treatment of cancer. Thus, peptide b11
might have such a potential. However, there seem multiple hurdles
for its application. First of all, expression levels of peptide b11
might need to be very high for growth suppression. We used
Figure 4. Stat5-binding short peptides inhibit the in vitro growth of Ba/F3 and TF-1 cells. Ba/F3 (A, C) or TF-1 (B) cells were retrovirally
transduced with the indicated peptides. GFP
+ transduced cells were FACS-sorted, cultured, and Trypan Blue-resistant live cells enumerated. (C)
Growth inhibition of Ba/F3 cells by shorter peptides derived from peptide b. Inhibitory ability was defined as the ratio of (relative cell number in
empty vector-transduced cells – relative cell number in peptide-transduced cells) to (relative cell number in empty vector-transduced cells –relative
cell number in PLC-b3-CT transduced cells).
doi:10.1371/journal.pone.0024995.g004
Figure 5. Expression of peptide b11 inhibits Stat5 phosphor-
ylation. Phospho-Stat5 Tyr
694 levels in Ba/F3 cells transduced with
peptide b11 or PLC-b3-CT were measured by immunoblotting (A) and
fluorescence microscopy (B) with anti-phospho-Stat5-Tyr
694. (A) Stat5
amounts were measured by reprobing. Phospho-Stat3-Tyr708 and Stat5
amounts were also measured. (B) Nuclei were stained with DAPI (blue).
The patterns of phospho-Stat5 were categorized into four (I-IV) and
their distributions are shown by scoring $200 cells.
doi:10.1371/journal.pone.0024995.g005
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However, it was difficult to inhibit Ba/F3 cell growth by using a
fusion peptide with the TAT protein translocation domain
[28](data not shown). Second, targeting specific cells is necessary.
These two problems might be resolved by fusing the peptide with a
membrane-localizing domain such as PH domain, as an
appropriately localized peptide inhibitor may need relatively
lower concentrations to be effective. Third, the peptide might need
to be stable within target cells.
In summary, this studyhasidentifiedminimal sequences required
for the tumor suppressor function of PLC-b3 that retain the Stat5-
binding and Stat5-inhibitory activities. One of the noncontiguous
Stat5-binding sequences that was also growth inhibitorywas a SHP-
1-binding site. However, the second SHP-1-binding site (peptide d)
was not growth inhibitory. The growth-inhibitory sequences can be
utilized as a potential regulator of hematopoietic cell growth.
Materials and Methods
Mice
PLC-b3
2/2 mice were described previously [29]. C57BL/6-Ly5.1
mice were purchased from The Jackson Laboratory. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The Animal Care and Use Committee of the La
Jolla Institute for Allergy and Immunology approved all mouse
experiments (permit number, AP122-TK1-0410).
Compounds
Wortmannin, Ly294062, SB203580 and SP600125 were
purchased from Calbiochem. U0126 was obtained from Cell
Signaling. All drugs were dissolved in DMSO and were diluted to
final concentrations of DMSO at less than 0.1%.
GST Fusion Pull-down Assay
PCR-amplified cDNA fragments using mouse PLC-b3 cDNA as
template were cloned into pGEX-3T vector [30]. The fusion
protein was induced in DH5a cells by 0.4 mM isopropyl -D-
thiogalactoside at 26uC for 3 h and purified by using glutathione-
agarose (Sigma). Binding assays were carried out as described [16]
with some minor modifications. Ba/F3 cells were lysed with lysis
buffer (20 mM Tris-HCl, pH8.0/150 mM NaCl/1 mM EDTA/
1% Nonidet P-40) containing protease inhibitors at 4uC for
20 min. Cell lysates from Ba/F3 cells with our without IL-3
stimulation were precleared with GST proteins, then mixed with
GST fusion proteins containing various portions of PLC-b3-CT
and incubated for 2 h at 4uC with rotation. The binding fraction
was washed six times with the lysis buffer without protease
Figure 6. Effects of peptide b11 and PLC-b3-CT on MAPKs and PI3K/Akt pathways. (A) Ba/F3 cells transduced with peptide b11 or PLC-b3-
CT were analyzed by SDS-PAGE. Phosphorylation levels of MAPKs and PI3K/Akt were evaluated by immunoblotting. (B) Ba/F3 transduced cells were
treated with wortmannin (3 nM), LY294062 (2 mM), SB203580 (0.1 mM), U0126 (1 mM) and SP600125 (0.1 mM). The live cells were counted on day 3
and day 7.
doi:10.1371/journal.pone.0024995.g006
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24995Figure 7. Peptide b11 inhibits in vitro and in vivo proliferation and differentiation of myeloid cells. (A) Lin
2 BM cells from old PLC-b3
2/2
mice were transduced with retroviruses coding for peptide b11 or PLC-b3-CT, FACS-sorted and cultured in IL-3, SCF and IL-6. (B) The transduced Lin
2
BM cells were cultured in methylcellulose medium containing SCF, IL-3, IL-6, and EPO. B, G, M, GM and GEMM represent BFU-E, CFU-G, CFU-M, CFU-
GM and CFU-GEMM. (C–E) Lin
2 BM cells from PLC-b3
2/2 mice were transduced with the indicated vectors and adoptively transferred to lethally
irradiated C57BL/6-Ly5.1 mice. Four months later, peripheral blood was analyzed by flow cytometry (D) for enumeration of CD11b
+ cells in CD45.2
+ or
CD45.2
2 cells. ***p,0.001. Numbers in upper and lower right quadrants in panel D represent percentages.
doi:10.1371/journal.pone.0024995.g007
Figure 8. Homology between peptide b of PLC-b3 and hypothetic proteins of parasites and bacteria. BLAST Search was performed using
peptide b as a query sequence. Identical residues are shown in a black background.
doi:10.1371/journal.pone.0024995.g008
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blotting, cell lysates were analyzed by SDS-PAGE and followed by
immnoblotting with anti-Stat5 (C-17) (Santa Cruz Biotechnology)
or anti-SHP-1(C-19) (Santa Cruz Biotechnology).
Flow Cytometry
Cells were stained with the indicated antibodies. Antibody
conjugates used for analysis were obtained from PharMingen
(APC-CD11b) or eBioscience (PE-CD45.2.). FACS Calibur (BD
Biosciences) was used for analysis.
PLC-b3
2/2 Lin
2 BM Cell Growth
Lin
2 BM cells from PLC-b3
2/2 mice were sorted using
EasySepH Magnet and mouse hematopoietic progenitor cell
enrichment kit (EasySepH Stem Cell Technologies) which
contained biotin-conjugated CD3, CD11b, CD19, CD45R, Gr-1
and Ter119. PLC-b3
2/2 Lin
2 BM cells were retrovirally
transduced with empty-vector, PLC-b3-CT or the Stat5 interac-
tive peptide (988–998). The transduced GFP
+ cells were sorted
into a 96 well plate at a density of 50 cells per well by FACS Diva
and cultured in the presence of IL-3, SCF and IL-6.
Transplantation of Hematopoietic Cells
We transplanted retrovirally transduced Lin- BM cells from old
($6 months) PLC-b3-/- mice (CD45.2, 3610
5 cells for each
recipient) into lethally (960 rad) irradiated C57BL/6-Ly5.1 mice
(8-12 week-old) together with 2610
6 Sca-1-depleted C57BL/6-
Ly5.1 helper BM cells. Sca-1
+ cells were depleted from BM cells
using MACSH and anti-Sca-1 microbeads (Miltenyi Biotech).
Immunoblotting
Ba/F3 cells transduced with a retrovirus vector (pMIG-PLC-b3-
CT or its shorter peptides) were used for the assay. Cell lysates
were analyzed by SDS-PAGE and followed by immunoblotting
with the following antibodies. Anti-p38 and anti-ERK were
purchased from Santa Cruz Biotechnology. Phospho-STAT5
(Tyr
694) was obtained from Upstate Biotechnology. Anti-JNK,
anti-PI3K p85, anti-Akt, anti-Stat3, anti-PDK-1, anti-phospho-
p38, anti-phospho-ERK, anti-phospho-JNK, anti-phospho-p85,
anti-phospho-Stat3 (Ser
727), anti-phospho-Akt (Thr
308), anti-
phospho-Akt (Ser
473) and anti-phospho-PDK-1were obtained
from Cell Signaling.
Retroviral Transduction
Sorted Lin
2 BM cells were incubated in a-MEM supplemented
with 1% FBS, SCF, IL-3 and IL-6 for 24 h, and then transduced
with a retrovirus vector (pMIG-PLC-b3-CT or its shorter peptides)
using TransITH-LT1 (Mirus Bio) in the presence of polybrene
(7.5 mg/ml) for 24 h. Transduced cells were further subjected to
liquid (in the presense of IL-3, IL-6 and SCF) or semi-solid cultures
(MethoCult
TM M3434 from Stem Cell Technologies). 48 h after
transduction, transduced (GFP
+) Ba/F3 cells and TF-1 cells were
sorted by FACS Diva into a 96 well plate at a density of 50 cells
per well for enumeration.
Immunofluorescence
Retrovirally transduced Ba/F3 cells were starved of IL-3
overnight. The next day, the cells were stimulated with IL-3 at
37uC for 5min. The cells were fixed with methanol and incubated
for 12 h at 4uC with anti-phospho-Stat5 (clone 8-5-2, Upstate
Biotechnology). Then the cells were washed and incubated with
Alexa Fluor 568-cojugated goat anti-mouse secondary antibody
(Invitrogen) at a dilution of 1:300 for 1 h at room temperature.
Immunofluorescence was observed with a Marianas microscope
(Intelligent Imaging Innovations, Inc).
Colony-Forming Assays
For myeloid colony-forming assays, 2610
3 Lin
2 BM cells or
2610
4 Lin
2 BM cells were transduced with retroviral vectors
and GFP
+ cells were FACS-sorted into MethoCult
TM M3434
(StemCell Technologies). After 7–12 days, colonies were scored
by microscopy.
Statistical Analysis
Student’s t-test or one way ANOVA were used for statistical
analysis. P,0.05 is considered significant.
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